{"id":"vinblastin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Leukopenia (granulocytopenia)","drugRate":"","severity":"common","organSystem":""},{"effect":"Alopecia","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Numbness of digits (paresthesias)","drugRate":"","severity":"common","organSystem":""},{"effect":"Loss of deep tendon reflexes","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral neuritis","drugRate":"","severity":"common","organSystem":""},{"effect":"Mental depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"","severity":"common","organSystem":""},{"effect":"Weakness","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Ileus","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Bacterial infectious disease","Bone marrow depression","Breastfeeding (mother)","Depressive disorder","Disorder of lung","Hepatic failure","Hyperbilirubinemia","Hyperuricemia","Impaired wound healing","Mycosis","Myocardial ischemia","Neutropenic disorder","Peripheral nerve disease","Pregnancy, function","Protozoal Infection","Severe Leukopenia","Thrombocytopenic disorder","Viral disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Cerebrovascular accidents","drugRate":"","severity":"serious"},{"effect":"Convulsions","drugRate":"","severity":"serious"},{"effect":"Hemorrhagic enterocolitis","drugRate":"","severity":"serious"},{"effect":"Eighth cranial nerve damage (deafness, balance difficulties)","drugRate":"","severity":"serious"},{"effect":"Angina pectoris","drugRate":"","severity":"serious"},{"effect":"Syndrome of inappropriate secretion of antidiuretic hormone","drugRate":"","severity":"serious"},{"effect":"Cellulitis (from extravasation)","drugRate":"","severity":"serious"},{"effect":"Phlebitis (from extravasation)","drugRate":"","severity":"serious"},{"effect":"Sloughing (from extravasation)","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Vinblastin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:30:25.397924+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:30:39.525981+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:30:30.945477+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vinblastin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:30:31.291739+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL268154/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:30:32.096618+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"f073b58e-56d6-4c8d-a2ce-b37719402d77","title":"VINBLASTINE SULFATE INJECTION [FRESENIUS KABI USA, LLC]"},"aiSummary":"Vinblastin, marketed by The Lymphoma Academic Research Organisation, is a chemotherapy agent primarily indicated for carcinoma of the female breast. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit the drug's competitive positioning and investor confidence.","ecosystem":[],"mechanism":{"target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1"},"_scrapedAt":"2026-03-28T02:11:32.331Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:30:39.526060+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Carcinoma of female breast","diseaseId":"carcinoma-of-female-breast","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gestational trophoblastic neoplasia","diseaseId":"gestational-trophoblastic-neoplasia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hodgkin's disease","diseaseId":"hodgkin's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Kaposi's sarcoma","diseaseId":"kaposi's-sarcoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Langerhans cell histiocytosis, disseminated","diseaseId":"langerhans-cell-histiocytosis-disseminated","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant tumor of testis","diseaseId":"malignant-tumor-of-testis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Metastatic Breast Carcinoma","diseaseId":"metastatic-breast-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mycosis fungoides","diseaseId":"mycosis-fungoides","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-Hodgkin's lymphoma","diseaseId":"non-hodgkin's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT04576117","phase":"PHASE3","title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma","enrollment":300},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT03585465","phase":"PHASE1, PHASE2","title":"Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-26","conditions":"Childhood Solid Tumor","enrollment":63},{"nctId":"NCT06745076","phase":"PHASE2","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-03-06","conditions":"Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","enrollment":125},{"nctId":"NCT01712490","phase":"PHASE3","title":"A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-11-09","conditions":"Hodgkin Lymphoma","enrollment":1334},{"nctId":"NCT07431060","phase":"NA","title":"Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2026-02-13","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":120},{"nctId":"NCT06831370","phase":"PHASE4","title":"A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-08-28","conditions":"Hodgkin Lymphoma","enrollment":124},{"nctId":"NCT06960577","phase":"PHASE3","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":"Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate","enrollment":150},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT06666348","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK","status":"RECRUITING","sponsor":"St. Justine's Hospital","startDate":"2026-01-12","conditions":"Pediatric Low-grade Glioma","enrollment":50},{"nctId":"NCT05137262","phase":"PHASE2","title":"A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-13","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":12},{"nctId":"NCT04685616","phase":"PHASE3","title":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-14","conditions":"Hodgkin Lymphoma","enrollment":1042},{"nctId":"NCT06290687","phase":"PHASE2","title":"Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-02-18","conditions":"Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT03033914","phase":"PHASE1, PHASE2","title":"A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01-25","conditions":"Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT00846742","phase":"PHASE2","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2009-06-05","conditions":"Hodgkin Lymphoma","enrollment":88},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":"Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","enrollment":994},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT06984146","phase":"PHASE2","title":"Nivo40-AVD for Advanced Classic Hodgkin Lymphoma","status":"RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2025-04-15","conditions":"Hodgkin Lymphoma, Adult","enrollment":54},{"nctId":"NCT03011528","phase":"PHASE2","title":"First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2016-12","conditions":"Ewing Sarcoma Family of Tumors","enrollment":45},{"nctId":"NCT06081400","phase":"NA","title":"Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-03-04","conditions":"Desmoid Tumor","enrollment":150},{"nctId":"NCT07234487","phase":"PHASE2","title":"Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2024-10-14","conditions":"Hodgkin Lymphoma","enrollment":178},{"nctId":"NCT02979522","phase":"PHASE1, PHASE2","title":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2017-09-06","conditions":"Hodgkin Disease","enrollment":59},{"nctId":"NCT07013565","phase":"PHASE2","title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2025-08-07","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":20},{"nctId":"NCT07209059","phase":"PHASE2","title":"PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2025-07-29","conditions":"Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT01812369","phase":"PHASE3","title":"Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2013-02","conditions":"Bladder Cancer","enrollment":500},{"nctId":"NCT03233347","phase":"PHASE2","title":"Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2017-10-13","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT07202819","phase":"NA","title":"Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-09-01","conditions":"Muscle Invasive Bladder Cancer","enrollment":76},{"nctId":"NCT04383743","phase":"PHASE2","title":"Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-24","conditions":"Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma","enrollment":17},{"nctId":"NCT07171827","phase":"NA","title":"Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Helwan University","startDate":"2023-03-01","conditions":"Anti-CD30, Brentuximab, Doxorubicin","enrollment":60},{"nctId":"NCT02670707","phase":"PHASE3","title":"Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2016-03-07","conditions":"Langerhans Cell Histiocytosis","enrollment":124},{"nctId":"NCT02758717","phase":"PHASE2","title":"Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2016-05-13","conditions":"Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma","enrollment":46},{"nctId":"NCT01876082","phase":"PHASE2","title":"PAZOPANIB Efficacy and Tolerance in Desmoids Tumors","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2012-09-18","conditions":"Progressive Desmoids Tumors","enrollment":72},{"nctId":"NCT03646123","phase":"PHASE2","title":"Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2019-01-28","conditions":"Hodgkin Lymphoma","enrollment":255},{"nctId":"NCT01771107","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-08","conditions":"AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma","enrollment":41},{"nctId":"NCT07120217","phase":"","title":"Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.","status":"COMPLETED","sponsor":"Federico II University","startDate":"2008-01-01","conditions":"Hodgkin Disease, Breast Cancer, Liposomal Doxorubicin","enrollment":200},{"nctId":"NCT03517137","phase":"PHASE2","title":"Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-08-01","conditions":"Advanced Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT05180825","phase":"PHASE2","title":"Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2022-05-05","conditions":"Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma","enrollment":134},{"nctId":"NCT03159897","phase":"PHASE3","title":"FIL Study on ABVD DD-DI as Upfront Therapy in HL.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2017-08-01","conditions":"Hodgkin Lymphoma","enrollment":500},{"nctId":"NCT00049595","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-08","conditions":"Lymphoma","enrollment":552},{"nctId":"NCT00379041","phase":"PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1993-09-01","conditions":"Lymphoma","enrollment":1158},{"nctId":"NCT03331341","phase":"PHASE1, PHASE2","title":"Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-01-09","conditions":"Classical Hodgkin Lymphoma","enrollment":50},{"nctId":"NCT00002462","phase":"PHASE3","title":"RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1989-09","conditions":"Lymphoma","enrollment":615},{"nctId":"NCT00005584","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-10","conditions":"Lymphoma","enrollment":1649},{"nctId":"NCT06263231","phase":"PHASE3","title":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intensity Therapeutics, Inc.","startDate":"2024-06-28","conditions":"Sarcoma,Soft Tissue","enrollment":333},{"nctId":"NCT06358573","phase":"PHASE2","title":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-24","conditions":"Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer","enrollment":54},{"nctId":"NCT06164275","phase":"PHASE2","title":"Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2024-02-06","conditions":"Classic Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT01868451","phase":"NA","title":"Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Hodgkin Lymphoma","enrollment":118},{"nctId":"NCT04506554","phase":"PHASE2","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2020-12-01","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":81},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT05008224","phase":"PHASE2","title":"Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-10-07","conditions":"Classical Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT06381570","phase":"EARLY_PHASE1","title":"Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas","status":"RECRUITING","sponsor":"Daniel Morgenstern","startDate":"2024-03-21","conditions":"Low-grade Glioma","enrollment":57},{"nctId":"NCT06377566","phase":"PHASE2","title":"A Study of BV-AVD in People With Bulky Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-17","conditions":"Hodgkin Lymphoma","enrollment":71},{"nctId":"NCT05481437","phase":"","title":"A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-08-01","conditions":"Hodgkin Lymphoma","enrollment":8},{"nctId":"NCT03004833","phase":"PHASE2","title":"Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2017-02-21","conditions":"Classical Hodgkin Lymphoma","enrollment":110},{"nctId":"NCT06857500","phase":"","title":"Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience","status":"COMPLETED","sponsor":"Federico II University","startDate":"2013-01-01","conditions":"Classic Hodgkin Lymphoma, Advanced Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT03058289","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","status":"COMPLETED","sponsor":"Intensity Therapeutics, Inc.","startDate":"2017-02-09","conditions":"Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma","enrollment":111},{"nctId":"NCT03674424","phase":"PHASE2","title":"Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2018-06-01","conditions":"Non-metastatic Muscle Invasive Bladder Cancer","enrollment":137},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT02710734","phase":"PHASE2","title":"Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2016-02-24","conditions":"Urothelial Carcinoma of the Bladder","enrollment":78},{"nctId":"NCT03712202","phase":"PHASE2","title":"Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-11-28","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma","enrollment":155},{"nctId":"NCT04638790","phase":"PHASE3","title":"First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)","status":"RECRUITING","sponsor":"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","startDate":"2020-02-01","conditions":"Hodgkin Lymphoma, Adult","enrollment":300},{"nctId":"NCT02177695","phase":"PHASE2","title":"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-08-28","conditions":"Bladder Cancer","enrollment":237},{"nctId":"NCT06486337","phase":"PHASE2","title":"CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"NHL","enrollment":197},{"nctId":"NCT05404945","phase":"PHASE2","title":"Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-26","conditions":"Classical Hodgkin Lymphoma","enrollment":44},{"nctId":"NCT06433362","phase":"PHASE2","title":"CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-01","conditions":"Peripheral T Cell Lymphoma","enrollment":115},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT02641314","phase":"PHASE2","title":"Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2016-12-22","conditions":"Recurrent Neuroblastoma","enrollment":18},{"nctId":"NCT00678327","phase":"PHASE3","title":"Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2008-08-29","conditions":"Lymphoma","enrollment":1202},{"nctId":"NCT06373055","phase":"","title":"Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-05-01","conditions":"Muscle-invasive Bladder Cancer","enrollment":250},{"nctId":"NCT03549715","phase":"PHASE1, PHASE2","title":"NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","startDate":"2018-12-06","conditions":"Infiltrating Bladder Urothelial Carcinoma","enrollment":121},{"nctId":"NCT06104878","phase":"","title":"A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2023-12-31","conditions":"Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT06269536","phase":"NA","title":"Stress-reducing Intervention in Urothelial Carcinoma","status":"RECRUITING","sponsor":"Comenius University","startDate":"2024-02-15","conditions":"Bladder Cancer","enrollment":50},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT02840409","phase":"PHASE2","title":"Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2016-08-01","conditions":"Low Grade Glioma","enrollment":109},{"nctId":"NCT06204614","phase":"EARLY_PHASE1","title":"Drug Screening Using IMD in Bladder Cancer","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2024-02-14","conditions":"Muscle Invasive Bladder Urothelial Carcinoma","enrollment":18},{"nctId":"NCT02969083","phase":"PHASE2","title":"Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma","status":"UNKNOWN","sponsor":"The European Uro-Oncology Group","startDate":"2018-05-28","conditions":"Upper Tract Urothelial Carcinoma","enrollment":200},{"nctId":"NCT01088750","phase":"PHASE4","title":"Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Christine Mauz-Körholz","startDate":"2009-11-01","conditions":"Lymphoma","enrollment":225},{"nctId":"NCT05627115","phase":"PHASE2","title":"Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2024-03-01","conditions":"Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT02181738","phase":"PHASE2","title":"Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-08-12","conditions":"Hodgkin Disease","enrollment":294},{"nctId":"NCT00352027","phase":"PHASE2","title":"Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2006-07-20","conditions":"Hodgkin's Lymphoma","enrollment":81},{"nctId":"NCT03912818","phase":"PHASE2","title":"Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-04-10","conditions":"Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT02343718","phase":"PHASE1","title":"Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2015-06-24","conditions":"Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours","enrollment":7},{"nctId":"NCT00488605","phase":"PHASE3","title":"H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2023-08-01","conditions":"Leukemia","enrollment":""},{"nctId":"NCT02412670","phase":"PHASE2","title":"Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2015-08-27","conditions":"High Grade Upper Tract Urothelial Carcinoma","enrollment":36},{"nctId":"NCT00003389","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-06-17","conditions":"Lymphoma","enrollment":854},{"nctId":"NCT01390584","phase":"PHASE2","title":"Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-05-24","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT00003027","phase":"PHASE3","title":"Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-11-13","conditions":"Melanoma (Skin)","enrollment":482},{"nctId":"NCT00003376","phase":"PHASE3","title":"Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1998-12-03","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer","enrollment":330},{"nctId":"NCT00003701","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Bladder Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-04-02","conditions":"Bladder Cancer, Urethral Cancer","enrollment":490},{"nctId":"NCT03226249","phase":"PHASE2","title":"PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2017-11-09","conditions":"Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT03472274","phase":"PHASE2","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","status":"COMPLETED","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2018-10-25","conditions":"Bladder Cancer","enrollment":101},{"nctId":"NCT01285817","phase":"PHASE2","title":"A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2011-01-12","conditions":"Survival Without Progression","enrollment":79},{"nctId":"NCT01700946","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-04-15","conditions":"Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT02104986","phase":"PHASE2","title":"A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2014-05-12","conditions":"Extra Cranial Non Seminomateous Malignant Germ Cell Tumour","enrollment":117},{"nctId":"NCT03580408","phase":"PHASE2","title":"Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-08-31","conditions":"Hodgkin Lymphoma, Coexisting Medical Conditions","enrollment":64},{"nctId":"NCT02292979","phase":"PHASE2","title":"Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-03","conditions":"Hodgkin Lymphoma","enrollment":170}],"_emaApprovals":[],"_faersSignals":[{"count":14,"reaction":"NEUTROPENIA"},{"count":13,"reaction":"NAUSEA"},{"count":13,"reaction":"OFF LABEL USE"},{"count":12,"reaction":"FATIGUE"},{"count":11,"reaction":"DIARRHOEA"},{"count":11,"reaction":"FEBRILE NEUTROPENIA"},{"count":10,"reaction":"ANAEMIA"},{"count":10,"reaction":"MYELODYSPLASTIC SYNDROME"},{"count":10,"reaction":"PRODUCT USE ISSUE"},{"count":10,"reaction":"THROMBOCYTOPENIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL268154"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":256,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Vinblastin","genericName":"Vinblastin","companyName":"The Lymphoma Academic Research Organisation","companyId":"the-lymphoma-academic-research-organisation","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:30:39.526060+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}